SAR-CoV-2 – Page 3 – Communicable Diseases Research

Genomic Diversity of SARS-CoV-2 in Algeria and North African Countries: What We Know So Far and What We Expect?

Article

Published on 2022-02-182022-10-29
Journal: Microorganisms [Category] COVID-19,

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library

Chemistry

Published on 2022-02-172022-10-31
Journal: Frontiers in Chemistry [Category] COVID-19,

Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey

Article

Published on 2022-02-102022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] Ageusia Anosmia BNT162b2 Clinical data collected conducted COVID-19 pandemic COVID-19 symptoms COVID-19-related symptoms cumulative Dyspnea Effectiveness Europe Fever Frequency Health Health surveillance health worker health workers incidence Infection infection spreading Italy less Mainz much lower offered percentage positive questionnaire reduced reductions in reported retrospective cohort study SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severity Spread subjects Surveillance survey Swab symptom severity symptomatic tested the SARS-CoV-2 United States university vaccination Vaccination Status Vaccine Verona worker York
[DOI] 10.3390/vaccines10020272 PMC 바로가기 [Article Type] Article

The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic

Microbiology

Published on 2022-02-102022-10-31
Journal: Frontiers in Microbiology [Category] COVID-19,

Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19 A Phase 2 Randomized Clinical Trial

경증에서 중등도의 COVID-19 A 2상 무작위 임상 시험에서 SARS-CoV-2 호흡기 바이러스 제거, 바이러스 배출 및 증상 지속 기간에서 니클로사미드 대 위약의 효능

Randomized Controlled Trial

Published on 2022-02-092022-09-10
Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료제,

[키워드] 1:1 95% CI accounted addition adverse event adverse events age All trial participants analyzed antiviral activity assigned blind by mouth calculated center Chain Reaction Characteristics clearance of SARS-CoV-2 clinical clinical trial confirmation contagious period cough COVID COVID-19 COVID-19 testing decrease determined by diagnose Duration duration of symptom Efficacy enrolled Enrollment exclusion criteria fecal Fecal sample finding group groups headache Headaches Hospitalization Importance in vitro individual Infection intention-to-treat investigators Laboratory Massachusett Massachusetts mean difference mean survival time measure men Mild mild to moderate Mild to moderate COVID-19 mild to moderate symptoms moderate Moderate COVID-19 MONITOR mouth network niclosamide no significant difference objective oral Oropharyngeal participant Participants Patient patients receiving placebo Phase 2 Placebo placebo group placebo-controlled clinical trial platform Point polymerase chain polymerase chain reaction positive primary end point proportion Randomized randomized clinical trial Randomly receive receiving Registration Relevance reported respiratory respiratory sample Respiratory samples Result Safe sample collection Sample size SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 clearance setting shedding significant effect significantly Standard of care statistically Symptom symptom duration symptom resolution Symptoms the placebo group therapy treat Treatment treatment for COVID-19 treatment groups Trial trial participants Tuft vaccination Viral viral clearance viral shedding was collected
[DOI] 10.1001/jamanetworkopen.2021.44942 PMC 바로가기 [Article Type] Randomized Controlled Trial

Persons tested for SAR-CoV-2 at a military treatment facility in Hawaii

하와이의 군사 치료 시설에서 SAR-CoV-2 검사를 받은 사람들

Research Article

Published on 2022-02-042022-09-12
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] 1:1 Active duty adjusted adjusted odds ratios age Analysis Care Caucasian patients center Characteristics close contact color Community contact with contribute COVID-19 COVID-19 pandemic COVID-19 test Defense Department diagnosed discrepancy evaluated explain facility Factor Gender Health Health care healthcare identify individual infection with COVID-19 Logistic regression male member Most patient Most patients Other outcomes Patient Person populations positive Positive test presenting primary determinant provide retrospective risk SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection symptom onset Symptoms tested Treatment veterans were used with COVID-19
[DOI] 10.1371/journal.pone.0263472 PMC 바로가기 [Article Type] Research Article

Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding

Article

Published on 2022-01-302022-10-28
Journal: Viruses [Category] COVID-19, SARS,

[키워드] ACE2 ACE2 binding ACE2 receptor administration amino acid replacement Analysis analyzed antibody antigenic antigenic escape approaches binding binding affinity binding free energy bioinformatics Cluster complexes computational analysis computational mutagenesis coronavirus disease Coronaviruses COVID-19 Deleterious Effect epitope Epitopes feature hACE2 human ACE2 receptor human cell identify impairment indicate Infection Interaction monoclonal multiple mutation multiple mutations Mutation Neutralizing neutralizing antibody Pandemics performed produced Protein RBD RBD mutation RBD variant reduce resolved responsible S-protein SAR-CoV-2 SARS-CoV-2 sequence spike Strains Structure the RBD the receptor-binding domain the SARS-CoV-2 the vaccine Trigger Vaccines variants of SARS-CoV-2 virus–host interactions
[DOI] 10.3390/v14020295 PMC 바로가기 [Article Type] Article

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

보조제 서브유닛 단백질 COVID-19 백신, SCB-2019의 효능: 2상 및 3상 다기관, 이중 맹검, 무작위 배정, 위약 대조 시험

Clinical Trial

Published on 2022-01-292022-09-11
Journal: Lancet (London, England) [Category] 변종, 임상,

[키워드] 1:1 95% CI alum assigned baseline Belgium biopharmaceutical Brazil caused chloride circulating Clover Coalition country COVID 19 COVID-19 COVID-19 case COVID-19 vaccine CpG Cutoff dose doses double-blind effective vaccine Effective vaccines Efficacy efficacy analysis elicited Endpoint enrolled EudraCT exclusion FIVE follow-up period groups Health health condition injection injection site pain intramuscular dose Local median Mild-to-moderate moderate-to-severe COVID-19 MOST multicentre notable Older pandemic participant per-protocol per-protocol population Phase 2 Placebo placebo recipients placebo-controlled trial predominant primary endpoints Protein provide randomisation randomised Randomly receive Registered RT-PCR Safe SAR-CoV-2 SARS CoV SARS-CoV-2 SCB-2019 second dose seronegative participant Seropositivity severe COVID-19 severity Sodium chloride South Africa subset subunit systemic adverse event systemic adverse events Vaccine vaccine efficacy vaccinee vaccinees variant virus virus variants viruses was done
[DOI] 10.1016/S0140-6736(22)00055-1 PMC 바로가기 [Article Type] Clinical Trial

Post-mortem Findings of Inflammatory Cells and the Association of 4-Hydroxynonenal with Systemic Vascular and Oxidative Stress in Lethal COVID-19 †

염증 세포의 부검 결과 및 치명적인 코로나19에서 4-하이드록시노넨알과 전신 혈관 및 산화 스트레스의 연관성 †

Article

Published on 2022-01-272022-09-11
Journal: Cells [Category] 바이오마커, 진단,

[키워드] 4-hydroxynonenal 4-hydroxynonenal (4-HNE) absence acute tubular necrosis affected alveolar damage analyzed astrocytes Autopsy Biomarker Biomarkers blood vessel blood vessels Brain cells COVID-19 detrimental died differential expression Diffuse alveolar damage dismutase edema edematous finding Granulocytes immune system Immunohistochemical analysis Infection inflammatory cell inflammatory cells inflammatory parameters kidneys lethal leukocyte lipid peroxidation lung Lungs mitochondrial MPO myeloperoxidase nine organ organs oxidative burst oxidative stress Patient reactive reactive oxygen species (ROS) SAR-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus Sepsis SOD2 Stress suggested Superoxide Superoxide Dismutase superoxide dismutase (SOD) survivor systemic the cells tissue Tubular Necrosis Vascular vascular stress
[DOI] 10.3390/cells11030444 PMC 바로가기 [Article Type] Article

The adaptation of SARS-CoV-2 to humans

SARS-CoV-2의 인간 적응

Review

Published on 2022-01-102022-09-10
Journal: Memórias do Instituto Oswaldo Cruz [Category] SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptation adaptive adaptive evolution addition antibodies anticipated autophagy Cell coronavirus death Defense Depletion escape Evidence functions Host host cell host cells Human Immunity immunogenic impairment include inhibiting interferon lymphocyte Mitochondria motifs Mutation mutation and variants occurred other coronaviruses overcome process of adaptation replicate resource respiratory respiratory tract SAR-CoV-2 SARS-CoV-2 severe acute respiratory syndrome Coronavirus triggering Usage Viral Viral RNA viral RNA detection virus
[DOI] 10.1590/0074-02760210127 PMC 바로가기 [Article Type] Review